| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,162 | 1,248 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | XFRA CAPITAL ADJUSTMENT INFORMATION - 11.11.2026 | 324 | Xetra Newsboard | Das Instrument 6XP SE0009973563 XSPRAY PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 11.11.2026 und ex Kapitalmassnahme am 12.11.2026 The instrument 6XP SE0009973563 XSPRAY PHARMA AB EQUITY... ► Artikel lesen | |
| 06.11. | XSpray Pharma AB: Xspray Pharma publishes Interim Report for the third quarter 2026 | 180 | GlobeNewswire (Europe) | July-September 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -39,323 thousand (-47,332) Earnings per share before dilution amounted to SEK?-0.83 (-1.25) Cash... ► Artikel lesen | |
| 06.11. | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 90 million with an over-allotment issue of approximately SEK 72 million | 213 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 05.11. | XSpray Pharma AB: Xspray Pharma notified that the FDA has commenced an inspection at NerPharMa's manufacturing facility | 366 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has today been informed by its contract manufacturer NerPharMa that the U.S. Food and Drug Administration (FDA) has commenced an unannounced follow-up... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 02.10. | XSpray Pharma AB: Xspray Pharma provides regulatory status update for Dasynoc and Nilopki | 392 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today provides an update on the regulatory status for its two lead product candidates, Dasynoc and Nilopki. The Company reiterates its plan to resubmit the New Drug Applications... ► Artikel lesen | |
| 20.08. | Xspray's Dasynoc approval bid foiled again by FDA's manufacturer concerns | 3 | FiercePharma | ||
| 19.08. | XSpray Pharma AB: Xspray Pharma receives Complete Response Letter (CRL) from FDA for Dasynoc | 1.051 | GlobeNewswire (Europe) | The FDA's Complete Response Letter relates to the previously communicated observations at NerPharMa, concerning outstanding GMP (Good Manufacturing Practice) observations, as well as a request for additional... ► Artikel lesen | |
| 05.08. | XSpray Pharma AB: Xspray Pharma Interim Report Second Quarter 2026 | 555 | GlobeNewswire (Europe) | April-June 2026, Group Net sales amounted to SEK 0 thousand (0) Earnings before tax amounted to SEK -39,794 thousand (-44,885) Earnings per share before dilution amounted to SEK -0.87 (-1.21) Cash flow... ► Artikel lesen | |
| 26.06. | XSpray Pharma AB: Xspray Pharma provides regulatory update on its US product candidates Nilopki and Dasynoc and notes continued progress with its third-party manufacturer NerPharMa | 680 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) provides an update on the FDA review of its two US new drug applications. For Nilopki®, Xspray has defined an approach to address the items raised... ► Artikel lesen | |
| 05.06. | XSpray Pharma AB: Xspray Pharma Receives CRL from U.S. FDA for Nilopki | 477 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology platform to develop improved versions of marketed protein kinase inhibitors (PKIs)... ► Artikel lesen | |
| 03.06. | XSpray Pharma AB: Xspray Pharma employees fully participate in market priced long term incentive programs, signaling strong confidence ahead | 291 | GlobeNewswire (Europe) | Xspray Pharma's two newly implemented long-term incentive programs, LTIP 2025/2028 and LTIP 2026/2029, have reached full participation from the employees to whom they were offered. Participating employees... ► Artikel lesen | |
| 12.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026 | 258 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 12 May 2026.Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 28.04. | XSpray Pharma AB: Interim Report First Quarter 2026 | 377 | GlobeNewswire (Europe) | January-March 2026, GroupNet sales amounted to SEK 0 thousand (0)Earnings before tax amounted to SEK -35,380 thousand (-42,321)Earnings per share before dilution amounted to SEK -0.85 (-1.14)Cash flow... ► Artikel lesen | |
| 23.04. | XSpray Pharma AB: Xspray's rights issue oversubscribed - over-allotment issue fully utilized | 332 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 14.04. | XSpray Pharma AB: FDA accepts trade name Nilopki for Xspray's drug candidate XS003 (nilotinib) | 892 | GlobeNewswire (Europe) | The US Food and Drug Administration (FDA) has accepted Nilopki® as the proprietary name for Xspray Pharma's drug candidate XS003 (nilotinib). Nilopki is an improved, amorphous formulation of nilotinib... ► Artikel lesen | |
| 31.03. | XSpray Pharma AB: Xspray publishes disclosure document regarding rights issue | 296 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 31.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 31.03.2026 | 459 | Xetra Newsboard | Das Instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY wird ex Kapitalmassnahme gehandelt am 31.03.2026 The instrument OJ3 SE0009779796 SEAFIRE CAPITAL SK 10 EQUITY is traded ex capital adjustment... ► Artikel lesen | |
| 26.03. | XSpray Pharma AB: Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased | 323 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 24.03. | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue | 415 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 11.03. | XSpray Pharma AB: Xspray Pharma: FDA accepts resubmitted application for market approval of Dasynoc - PDUFA date August 25, 2026 | 674 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has accepted Xspray Pharma's resubmitted New Drug Application (NDA) for Dasynoc® for review under the 505(b)(2) procedure. The FDA has set a PDUFA date of... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 2,728 | -0,80 % | Evotec-Aktie: Gewinn- und Umsatzrekord? | Die Aktie des Hamburger Wirkstoffforschers Evotec bleibt ein spannender, aber risikoreicher Titel am deutschen Aktienmarkt. Nach schwierigen Monaten sorgen erste operative Fortschritte, neue Partnerschaften... ► Artikel lesen | |
| BB BIOTECH | 57,50 | -0,17 % | Christian Koch, Leiter BB Biotech Team bei Bellevue Asset Management, im Interview | von Robert Jakob Moneycab.com: Herr Koch, acht bestehende Beteiligungen verkauft, zwölf neue Positionen aufgebaut, das sieht nach einer grösseren Rochade aus? Die Veränderungen spiegeln unser aktives... ► Artikel lesen | |
| MODERNA | 179,14 | -0,08 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 36,890 | +0,71 % | 99 Millionen Dollar mit neuer Gentherapie: Vertex und CRISPR Therapeutics legen zu - Mesoblast wächst um 44 Prozent | ||
| NANOREPRO | 1,395 | -0,71 % | NanoRepro nach starkem H1-Bericht: Diese Marke entscheidet jetzt | ||
| AAP IMPLANTATE | 1,440 | -3,36 % | aap Implantate - Aktie vor Neubewertung? CEO und COO im Interview: "Die Basis steht, jetzt schalten wir auf Wachstum." | Eine spannende Sondersituation zeichnet sich derzeit bei der aap Implantate AG (ISIN: DE000A3H2101) ab: Nach Jahren der Restrukturierung und hohen regulatorischen Aufwendungen hat der Berliner Spezialist... ► Artikel lesen | |
| INFLARX | 1,026 | +1,89 % | InflaRx im Check: Izicopan rückt vor, der Chart bleibt unter Druck | ||
| TEMPUS AI | 58,33 | +0,60 % | Tempus AI to receive $200M as AstraZeneca extends oncology deal | ||
| EDITAS MEDICINE | 1,675 | +3,40 % | Editas Medicine, Inc.: Editas Medicine Receives Approval to Initiate First-In-Human Clinical Trial of EDIT-401 in Patients with Hyperlipidemia | Phase 1/2 clinical trial of EDIT-401 cleared to initiate dosing in patients who require additional LDL-C lowering Company remains on track to begin patient dosing this year and report initial safety... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 56,00 | +0,07 % | 50 Prozent der neuen US-Arzneien waren Orphan Drugs: Warum BioMarin, Vertex und NurExone kleine Märkte anders entwickeln | ||
| CARDIOL THERAPEUTICS | 0,873 | +0,81 % | Bayer, Cardiol Therapeutics, Novartis - Biotech-Aktien und Pharmariesen im Wettlauf ums Herz | Erstellt und veröffentlicht im Auftrag von Cardiol Therapeutics Die Kardiologie gehört zu den spannendsten Feldern der Pharmabranche. Vier Tage in Chicago haben gezeigt, wie viel Bewegung in der Herzmedizin... ► Artikel lesen | |
| EVONEXT | 2,460 | 0,00 % | Adhoc: EvoNext Holdings SA: EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26 | EvoNext Holdings SA / Key word(s): Merger
EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26
16-Nov-2026 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| IDORSIA | 4,150 | -0,19 % | Idorsia Pharmaceuticals Ltd: Breakthrough Therapy Designation granted by the FDA for daridorexant in pediatric insomnia disorder | The FDA recognizes through this designation both the clinical evidence supporting daridorexant and the significant unmet medical need in pediatric insomnia, where no FDA-approved pharmacological treatments... ► Artikel lesen | |
| MYRIAD GENETICS | 5,100 | +1,15 % | Myriad Genetics auf Stephens-Konferenz: Verstärkter Fokus auf Onkologie | ||
| TELIX PHARMACEUTICALS | 7,986 | -1,40 % | Telix auf der Bell Potter Healthcare Conference: Starkes Wachstum, gesicherte Lieferketten und Zulassungsdynamik |